Categories
Change Password!
Reset Password!
Intravenous use of Eptinezumab every
12 weeks can be used as a preventive therapy for migraine.
Administration of eptinezumab (humanized anti-CGRP
monoclonal antibody) intravenously (IV) every
12 weeks was found to be safe with clinically effective results in cases of
episodic or chronic migrane, as per a integrated analysis issued in The
Journal of Headache and Pain.
To examine the safety and tolerability of eptinezumab, Timothy R. Smith et al.
recruited 2867
patients with migraine.
Out of the total eptinezumab was administered in 2076 patients (4797 infusions) and placebo in 791 patients (1675 infusions). Overall adverse events (AEs) not related to the eptinezumab has been presented in the following table :
About ≥2% of patients in the eptinezumab 300-mg group had
nasopharyngitis and with a frequency of minimum of 2 percentage points more as
compared to placebo group; nevertheless, in most patients its occurrence was
considered linked with study drug. While none of the patients in placebo group
had hypersensitivity, about 1.1% patients reported as having hypersensitivity
in eptinezumab group. Most hypersensitivity reactions were not severe and
managed with usual medical therapy or observation without therapy, typically in
a day.
The Journal of Headache and Pain
Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials
Timothy R. Smith et al.
Comments (0)